Short answer: finasteride takes months, not weeks. The pivotal trials that got this drug FDA-approved for hair loss measured outcomes at 12 and 24 months — not 4 weeks. Here's the honest month-by-month picture, including the "dread shed" that makes about a third of patients quit too early.
Male pattern hair loss (androgenetic alopecia) is driven largely by dihydrotestosterone (DHT) binding to follicular androgen receptors and progressively shrinking the hair follicle — a process called miniaturization. Finasteride is a 5-alpha reductase inhibitor: it blocks the enzyme that converts testosterone to DHT, reducing scalp DHT by roughly 60–70% at 1mg daily. With DHT suppressed, the miniaturization process slows, stops, or partially reverses. But follicular cycles are long — growth phase is 2–6 years, rest phase 3 months — so benefit is measured in months, not weeks.
Nothing visible. DHT levels drop within days, but follicles haven't responded yet. Anyone promising visible results at 4 weeks is selling something.
Roughly 30–50% of patients notice a temporary increase in shedding in weeks 2–12. This is the dreaded shed. Mechanism: finasteride pushes resting-phase (telogen) hairs out of the follicle so new, healthier growth-phase (anagen) hairs can replace them. It feels like a disaster. It's usually the opposite. The shed typically lasts 2–8 weeks.
Shedding slows and stabilizes. You probably still don't see regrowth, but the rate of loss is noticeably less. Many patients at this stage report "I'm not shedding as much in the shower anymore." This is the first sign the drug is working.
For responders, fine, short, unpigmented (vellus) hairs start appearing in previously thinning areas, particularly the crown and mid-scalp. Over time these thicken and pigment. The Kaufman et al. JAAD trials showed statistically significant increase in hair count at 6 months that continued through 24 months.
The long-tail gains. New hairs continue thickening, and additional follicles transition back into growth phase. Most patients reach near-maximum benefit by 18–24 months. A 10-year follow-up study in JAAD showed sustained benefit over a decade of continuous use.
Maintenance. You're preserving what you've got and slowly adding marginal gains. Discontinuation at any point means the DHT suppression ends and most of the regained hair sheds within 6–12 months.
In the FDA pivotal trials, about 48% of men at 1 year and up to 66% at 2 years showed visible regrowth on finasteride 1mg. When you include the "no-further-loss" group (stabilization, which is still a win in a progressive disease), about 80–90% respond in some way. That leaves 10–20% of men who don't respond meaningfully at 12 months on monotherapy.
Predictors of better response:
Predictors of worse response: extensive baldness (the follicle is already gone — no drug revives a scarred/terminal follicle), frontal hairline recession (generally harder to treat than the crown), and poor adherence.
If you're going to have side effects, they usually show up in the first 3 months. The FDA label for Propecia reports sexual side effects in 1.8% of trial participants — decreased libido, erectile changes, ejaculate volume changes — all of which were generally reversible after stopping. The NIH StatPearls finasteride review discusses the broader profile, including rare reports of persistent symptoms after discontinuation (post-finasteride syndrome), which remains a debated area.
Practical guidance: if you're 3 months in and haven't had side effects, you're probably going to tolerate the medication long-term. If you do have side effects, they usually resolve within weeks to a few months of stopping.
Before concluding "it's not working," audit adherence. Missing even a few doses per week meaningfully reduces DHT suppression. If you've been consistent and still see no benefit, options include:
No — it works on a similar timeline. What it changes is systemic exposure: topical finasteride (compounded, or the commercial formulations in development) produces comparable scalp DHT reduction with much less serum DHT reduction. That means similar hair-loss benefit with a lower sexual side-effect risk. Timeline is still measured in months. It's a reasonable option for patients who want to minimize systemic exposure or who had sexual side effects on oral finasteride.
You see yourself in the mirror every day — which makes gradual change nearly invisible. Take standardized baseline photos (front, top, crown — same lighting, same distance, same hair state). Repeat monthly. At month 6 and month 12, compare back to baseline. This is the single best way to know whether you're a responder, because week-to-week change is too subtle to notice in real time.
If you're looking to start finasteride, our $45 hair loss telehealth visit covers:
A 90-day finasteride supply at most pharmacies is $10–20 with GoodRx. Combined with the $45 visit, that's a yearly cost most patients can plan around.
No — follicular cycles are the speed limit. You can maximize results by being consistent, combining with minoxidil, and managing scalp health (avoiding harsh styling, treating seborrheic dermatitis if present).
No. The 5mg dose (Proscar, for BPH) is not more effective for hair loss — the DHT suppression curve plateaus at 1mg. You'd get the same benefit and slightly more systemic exposure. Stick with 1mg.
Most likely normal. Unless it's associated with scalp pain, scarring, bald patches, or systemic symptoms (fatigue, weight changes, thyroid symptoms), stay the course and check in with your provider.
Postmenopausal women can, off-label — typically at 1.25–5mg daily in research. Premenopausal women generally should not (teratogenic risk). Oral minoxidil and spironolactone are more common first-line options in women.
It has been studied for 10+ years of continuous use (see JAAD 10-year trial). Most patients tolerate it indefinitely. Monitor PSA if over 40 — finasteride lowers PSA by about 50%, which matters for prostate cancer screening interpretation.